ABUS Stock Analysis: Arbutus Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 944m USD | 12M Return: 45.5% | CA03879J1003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.59M
Qual. Beats: 0
Rev. Trend: 53.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a U.S.-based, clinical-stage biopharmaceutical company focused on developing novel therapeutics for infectious diseases, with a primary emphasis on chronic Hepatitis B virus (HBV). Its pipeline includes Imdusiran, a subcutaneously-delivered RNAi therapeutic in Phase 2a trials designed to suppress HBV antigens, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b trials aimed at reactivating HBV-specific immune response. The company also holds a licensing agreement with Alnylam Pharmaceuticals related to LNP delivery technology. Originally incorporated in 2005 as Tekmira Pharmaceuticals, Arbutus is headquartered in Warminster, Pennsylvania, and operates within the biotechnology sub-industry of the healthcare sector, where companies typically rely on partnerships, licensing deals, and capital markets to fund lengthy and costly drug development cycles before achieving commercialization.
- Imdusiran Phase 2a functional cure data readout approaches
- Alnylam LNP licensing royalty revenue declines post-pandemic
- HBV competitive landscape intensifies from Vir and GSK pipeline
| Net Income: 153.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 49.38 > 1.0 |
| NWC/Revenue: 148.9% < 20% (prev 636.3%; Δ -487.5% < -1%) |
| CFO/TA -0.09 > 3% & CFO -24.6m > Net Income 153.1m |
| Net Debt (-88.4m) to EBITDA (153.2m): -0.58 < 3 |
| Current Ratio: 81.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (197.5m) vs 12m ago 2.64% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 96.33% > 50% (prev 14.93%; Δ 81.40% > 0%) |
| Interest Coverage Ratio: 2.01k > 6 (EBIT TTM 153.1m / Interest Expense TTM 76.0k) |
| A: 0.99 (Total Current Assets 273.9m - Total Current Liabilities 3.36m) / Total Assets 274.0m |
| B: -4.44 (Retained Earnings -1.22b / Total Assets 274.0m) |
| C: 0.81 (EBIT TTM 153.1m / Avg Total Assets 188.6m) |
| D: 16.92 (Book Value of Equity 258.7m / Total Liabilities 15.3m) |
| Altman-Z'' = 15.24 = AAA |
As of August 22, 2026, the stock is trading at USD 5.21 with a total of 18,069,050 shares traded. Over the past week, the price has changed by +11.56%, over one month by +15.27%, over three months by +17.34% and over the past year by +45.53%.
Current recommended Stop Loss: 4.90 (which is 6% or 1.5 ATR below the current price).
Arbutus Biopharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ABUS.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.6 | 6.5% |
P/E Trailing = 6.038
P/E Forward = 10.2459
P/S = 5.1933
P/B = 3.8005
Revenue TTM = 181.7m USD
EBIT TTM = 153.1m USD
EBITDA TTM = 153.2m USD
Long Term Debt = 3.11m USD (estimated: total debt 3.62m - short term 514k)
Short Term Debt = 514k USD (from shortTermDebt, last quarter)
Debt = 4.26m USD (from shortLongTermDebtTotal, last quarter) + Leases 631k
Net Debt = -88.4m USD (calculated: Debt 4.26m - CCE 92.6m)
Enterprise Value = 855.4m USD (943.7m + Debt 4.26m - CCE 92.6m)
Interest Coverage Ratio = 2.01k (Ebit TTM 153.1m / Interest Expense TTM 76.0k)
EV/FCF = -34.74x (Enterprise Value 855.4m / FCF TTM -24.6m)
FCF Yield = -2.88% (FCF TTM -24.6m / Enterprise Value 855.4m)
FCF Margin = -13.55% (FCF TTM -24.6m / Revenue TTM 181.7m)
Net Margin = 84.23% (Net Income TTM 153.1m / Revenue TTM 181.7m)
Gross Margin = unknown ((Revenue TTM 181.7m - Cost of Revenue TTM 363k) / Revenue TTM)
Tobins Q-Ratio = 3.12 (Enterprise Value 855.4m / Total Assets 274.0m)
Interest Expense / Debt = 1.79% (Interest Expense 76.0k / Debt 4.26m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 121.0m (EBIT 153.1m * (1 - 21.00%))
Current Ratio = 81.42 (Total Current Assets 273.9m / Total Current Liabilities 3.36m)
Debt / Equity = 0.02 (Debt 4.26m / totalStockholderEquity, last quarter 258.7m)
Debt / EBITDA = -0.58 (Net Debt -88.4m / EBITDA 153.2m)
Debt / FCF = 3.59 (negative FCF - burning cash) (Net Debt -88.4m / FCF TTM -24.6m)
Total Stockholder Equity = 168.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 81.13% (Net Income 153.1m / Total Assets 274.0m)
RoE = 90.98% (Net Income TTM 153.1m / Total Stockholder Equity 168.2m)
RoCE = 89.38% (EBIT 153.1m / Capital Employed (Equity 168.2m + L.T.Debt 3.11m))
RoIC = 46.16% (NOPAT 121.0m / Invested Capital 262.1m)
WACC = 9.29% (E(943.7m)/V(948.0m) * Re(9.33%) + D(4.26m)/V(948.0m) * Rd(1.79%) * (1-Tc(0.21)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 83.99 | Cagr: 5.35%
[DCF] Fair Price = unknown (Cash Flow -24.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 53.68 | Revenue CAGR: 99.17% | SUE: 0.00 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.03 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.03 | Chg30d=-0.29% | Revisions=+0% | GrowthEPS=+540.4% | GrowthRev=+1208.8%
EPS next Year (2027-12-31): EPS=-0.11 | Chg30d=+10.48% | Revisions=+25% | GrowthEPS=-110.8% | GrowthRev=-97.8%